This multicentre, open-label phase 1/2 trial determined safety and efficacy of weekly carfilzomib plus cyclophosphamide-dexamethasone (wKCyd) in newly diagnosed multiple myeloma (NDMM) patients aged ≥65 years or transplant ineligible. Patients received wKCyd for up to nine 28-day cycles, followed by maintenance with carfilzomib until progression/intolerance. The phase 1 portion used a 3+3 dose-escalation scheme to determine the maximum tolerated dose of weekly carfilzomib: 12 patients received wKCyd with carfilzomib doses of 45, 56 and 70 mg/m 2. The recommended phase 2 dose was established at 70 mg/m 2 and 54 patients (phase 1 and 2) received weekly carfilzomib 70 mg/m 2: 85% of them achieved ≥partial response (PR), 66% ≥very good PR, 30%≥near-complete response (CR) and 15% CR. Responses improved in 40 patients who started maintenance: 98% achieved ≥PR, including 29% CR and 10% stringent CR. After a median follow-up of 18 months, the 2-year progression-free survival and overall survival rates were 53.2% and 81%, respectively. The most frequent grade 3-5 toxicities were neutropenia (22%) and cardiopulmonary adverse events (9%). This is the first study of weekly carfilzomib plus an alkylating agent in elderly patients with NDMM. wKCyd was effective, with an acceptable risk/benefit ratio, and thus can be a valid option in this setting.
Phase 1/2 study of weekly carfilzomib, cyclophosphamide, dexamethasone in newly diagnosed transplant-ineligible myeloma
Bringhen S.
First
;D'Agostino M.;Palumbo A.;Boccadoro M.Last
2018-01-01
Abstract
This multicentre, open-label phase 1/2 trial determined safety and efficacy of weekly carfilzomib plus cyclophosphamide-dexamethasone (wKCyd) in newly diagnosed multiple myeloma (NDMM) patients aged ≥65 years or transplant ineligible. Patients received wKCyd for up to nine 28-day cycles, followed by maintenance with carfilzomib until progression/intolerance. The phase 1 portion used a 3+3 dose-escalation scheme to determine the maximum tolerated dose of weekly carfilzomib: 12 patients received wKCyd with carfilzomib doses of 45, 56 and 70 mg/m 2. The recommended phase 2 dose was established at 70 mg/m 2 and 54 patients (phase 1 and 2) received weekly carfilzomib 70 mg/m 2: 85% of them achieved ≥partial response (PR), 66% ≥very good PR, 30%≥near-complete response (CR) and 15% CR. Responses improved in 40 patients who started maintenance: 98% achieved ≥PR, including 29% CR and 10% stringent CR. After a median follow-up of 18 months, the 2-year progression-free survival and overall survival rates were 53.2% and 81%, respectively. The most frequent grade 3-5 toxicities were neutropenia (22%) and cardiopulmonary adverse events (9%). This is the first study of weekly carfilzomib plus an alkylating agent in elderly patients with NDMM. wKCyd was effective, with an acceptable risk/benefit ratio, and thus can be a valid option in this setting.File | Dimensione | Formato | |
---|---|---|---|
[Published Vsn and Supplementary Appendix] Bringhen et al - Phase I II Study wKcyd for MM - leu2017327.pdf
Accesso riservato
Descrizione: [Restricted access - Published vsn.] Bringhen S et al. Leukemia . 2018 Apr;32(4):979-985. doi: 10.1038/leu.2017.327. Epub 2017 Nov 16. © 2018 Macmillan Publishers Limited, part of Springer Nature. All rights reserved. Available at: https://www.nature.com/articles/leu2017327 | https://doi.org/10.1038/leu.2017.327
Tipo di file:
PDF EDITORIALE
Dimensione
602.42 kB
Formato
Adobe PDF
|
602.42 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
[Author Vsn and Supplementary Appendix] Bringhen et al - 2018 - Leukemia - Phase 1 2 study of weekly carfilzomib - Post print a.pdf
Accesso riservato
Descrizione: [Author vsn. and Supplementary Appendix - Restricted access] Bringhen S et al. Leukemia . 2018 Apr;32(4):979-985. doi: 10.1038/leu.2017.327. Epub 2017 Nov 16. © 2018 Macmillan Publishers Limited, part of Springer Nature. All rights reserved. The published version is available at: https://www.nature.com/articles/leu2017327 | https://doi.org/10.1038/leu.2017.327
Tipo di file:
POSTPRINT (VERSIONE FINALE DELL’AUTORE)
Dimensione
1.21 MB
Formato
Adobe PDF
|
1.21 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
[Pre-print Vsn and Suppl Appendix] Bringhen S et al - 2018 - Leukemia - Phase 1 2 study of weekly carfilzomib.pdf
Accesso aperto
Descrizione: [Pre-print vsn. and Supplementary Appendix] Bringhen S et al. Leukemia . 2018 Apr;32(4):979-985. doi: 10.1038/leu.2017.327. Epub 2017 Nov 16. © 2018 Macmillan Publishers Limited, part of Springer Nature. All rights reserved. This is not the final published version. The published version is available at: https://www.nature.com/articles/leu2017327 | https://doi.org/10.1038/leu.2017.327
Tipo di file:
PREPRINT (PRIMA BOZZA)
Dimensione
1.19 MB
Formato
Adobe PDF
|
1.19 MB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.